Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Cash & Equivalents (2017 - 2025)

Autolus Therapeutics' Cash & Equivalents history spans 8 years, with the latest figure at $104.1 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 54.2% year-over-year to $104.1 million; the TTM value through Dec 2025 reached $104.1 million, down 54.2%, while the annual FY2025 figure was $104.1 million, 54.2% down from the prior year.
  • Cash & Equivalents reached $104.1 million in Q4 2025 per AUTL's latest filing, up from $86.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $758.5 million in Q1 2024 to a low of $86.1 million in Q3 2025.
  • Average Cash & Equivalents over 5 years is $308.6 million, with a median of $256.4 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 156.25% in 2024, then crashed 87.37% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $310.3 million in 2021, then rose by 23.23% to $382.4 million in 2022, then plummeted by 37.36% to $239.6 million in 2023, then decreased by 5.09% to $227.4 million in 2024, then plummeted by 54.2% to $104.1 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Cash & Equivalents are $104.1 million (Q4 2025), $86.1 million (Q3 2025), and $123.8 million (Q2 2025).